Andere talen Aeterna Zentaris Inc. Nasdaq

Aandelen

AEZS

CA0079756007

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 17-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,52 ^USD	-0,77%		+3,52%	+14,52%

15/05	MT Newswires Canada Overnight Aandelen om in de gaten te houden: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	MT
15/05	Aeterna Zentaris Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Aeterna Zentaris Finalizes Some Details for Ceapro Merger	17/05
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	17/05
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro	17/05
Aeterna Zentaris : Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 - Form 6-K	16/05
Aeterna Zentaris : Audited Consolidated Financial Statements of Ceapro Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 - Form 6-K	15/05
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	15/05
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Aeterna Zentaris Reports First Quarter 2024 Financial Results	15/05
Aeterna Zentaris : MATERIAL CHANGE REPORT - Form 6-K	09/05
Aeterna Zentaris Announces Effective Date of Share Consolidation	01/05
North American Morning Briefing : Powell Awaited -2-	03/04
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03
Aeterna Zentaris : Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Form 6-K	27/03
Aeterna Zentaris : Consolidated Financial Statements As of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 - Form 6-K	27/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aeterna Zentaris Inc. Nasdaq

Aandelen

AEZS

CA0079756007

Andere talen

Filters